Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02389517 · OUTCOME

Duration of MRD-negative Disease

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant · Source last updated 2026-01-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
years
Interval / dispersion
Full Range
Time frame
every 28 days, up to 2 years

What was measured

Duraion of MRD-negativie disease was defined as the duration from the date of MRD negative to the date of diseae progression or date of last clinical follow up.

Analysis population: Patients who had MRD-negative were analyzed.

Groups in this outcome

Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)

Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). Ixazomib Citrate: Given PO Lenalidomide: Given PO Dexamethasone: Given PO

Arm II (Lenalidomide)

Patients receive lenalidomide PO as in Arm I. Lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)2
Arm II (Lenalidomide)4

Reported measurements

Source class 1
Values in years · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)1.91Not reported1.841.98Not reported
Arm II (Lenalidomide)1.98Not reported1.822.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.84
        upper Limit
        1.98
        value
        1.91
      2. group Id
        OG001
        lower Limit
        1.82
        upper Limit
        2.0
        value
        1.98
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    2. group Id
      OG001
      value
      4
    units
    Participants
description
Duraion of MRD-negativie disease was defined as the duration from the date of MRD negative to the date of diseae progression or date of last clinical follow up.
dispersion Type
Full Range
groups
  1. description
    Patients receive ixazomib citrate PO on days 1, 8, and 15, lenalidomide PO QD on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22 (of courses 1-4 only). Ixazomib Citrate: Given PO Lenalidomide: Given PO Dexamethasone: Given PO
    id
    OG000
    title
    Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone)
  2. description
    Patients receive lenalidomide PO as in Arm I. Lenalidomide: Given PO
    id
    OG001
    title
    Arm II (Lenalidomide)
param Type
MEDIAN
population Description
Patients who had MRD-negative were analyzed.
reporting Status
POSTED
time Frame
every 28 days, up to 2 years
title
Duration of MRD-negative Disease
type
SECONDARY
unit Of Measure
years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice